SYMBICORT TURBUHALER 320/9UG -60DOSES

KSh6,080.00

SYMBICORT combines an ICS, budesonide and a LABA medicine, formoterol. LABA medicines, such as formoterol, when used alone can increase the risk of hospitalizations and death from asthma problems.This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema.

SKU: DP13412 Category:

INDICATIONS.

Asthma

Symbicort Turbohaler is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:

– patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.

or

– patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.

Chronic Obstructive Pulmonary Disease (COPD)

Symbicort Turbohaler is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) <70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.

DOSAGE.

Patients should be advised to have their separate rapid-acting bronchodilator available for rescue use at all times.

Recommended doses:

Adults (18 years and older): 1-2 inhalations twice daily. Some patients may require up to a maximum of 4 inhalations twice daily.

Adolescents (12 – 17 years): 1-2 inhalations twice daily.

In usual practice when control of symptoms is achieved with the twice daily regimen, titration to the lowest effective dose could include Symbicort given once daily, when in the opinion of the prescriber, a long-acting bronchodilator in combination with an inhaled corticosteroid would be required to maintain control.

Increasing use of a separate rapid-acting bronchodilator indicates a worsening of the underlying condition and warrants a reassessment of the asthma therapy.

Children (6 years and older): A lower strength (100 micrograms/6 micrograms/inhalation) is available for children 6-11 years.

Children under 6 years: As only limited data are available, Symbicort is not recommended for children younger than 6 years.

ADVERSE EFFECTS.

Thite patches on tongue/in mouth, signs of infection (such as sore throat that doesn’t go away, fever), mental/mood changes (such as nervousness), trouble sleeping, vision problems (such as blurred vision), increased thirst/urination, muscle cramps, shaking (tremors).

Breathing problems/asthma immediately after use.

0